Company Filing History:
1 out of 934 
1 out of 2 Years Active: 2024
Title: The Innovative Contributions of Paul Orban in Antibody Research
Introduction: Paul Orban is a notable inventor based in Vancouver, Canada, recognized for his significant contribution to the field of immunology through his patent on anti-HLA-A2 antibodies. His work has implications for the development of therapeutic strategies in cancer treatment by targeting specific antigens.
Latest Patents: Orban holds a patent titled "Anti-HLA-A2 antibodies and methods of using the same." This patent provides humanized anti-HLA-A2 antibodies, which play a crucial role in forming an antigen-binding domain of chimeric antigen receptors (CARs). These CARs can be expressed in human cells, enabling the specific binding to HLA-A2. The patent also outlines modified cells that incorporate these antibodies and CARs, along with methods for their application in medical research and therapy.
Career Highlights: Throughout his career, Paul Orban has collaborated with prominent institutions such as the University of British Columbia and CDRD Ventures Inc. His work in these organizations has enabled him to explore innovative solutions in the field of antibody development, laying the groundwork for future advancements in cancer therapies.
Collaborations: Orban has shared his expertise with notable colleagues including Megan Levings and Nicholas Dawson. Their collaborations have fostered an environment of innovation and have been instrumental in furthering research in the field of immunology.
Conclusion: Paul Orban's contributions to the field of science, particularly through his patent on anti-HLA-A2 antibodies, highlight his role as an inventor dedicated to advancing medical research. His collaborative efforts and innovations continue to influence the landscape of therapeutic advancements in immunology, ultimately impacting patient care and treatment outcomes.